October 8, 2021

POP BIO awarded $599,981 Phase 1 SBIR Award to Develop Thermostable COVID-19 Vaccine

BUFFALO, N.Y. — POP Biotechnologies Inc. (POP BIO) received a $599,981, two-year Phase I Small Business Innovation Research (SBIR) under Award No. 1R43AI165089-01, supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to pursue development of a potentially life-saving vaccine technology to address the ongoing pandemic crisis caused by Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the microbe responsible for the coronavirus disease 2019 (COVID-19), through the development of a thermostable recombinant nanoparticle vaccine.
February 23, 2021

COVID-19 vaccine developed by UB startup approved for human trials

EuCorVac-19, a next-generation particle-based COVID-19 vaccine incorporating POP BIO's SNAP technology has gained regulatory approval for Phase I/II studies